TY - JOUR AU - He, Wang AB - INTRODUCTIONBladder cancer is the tenth most common cancer worldwide.1 Transurethral resection of bladder tumor (TURBT) with instillation of chemotherapy is the chief treatment for nonmuscle invasive bladder cancer (NMIBC).2 The main purpose of instillation of chemotherapy is to reduce recurrence. Previous studies have shown that compared with TURBT alone, the instillation of chemotherapy after TURBT can reduce recurrence in NMIBC patients.3–7 Epirubicin and pirarubicin are two of the most effective instillation chemotherapy agents and a single immediate instillation of chemotherapy with epirubicin and pirarubicin can prolong recurrence‐free survival in NMIBC patients.8 Furthermore, a single postoperative instillation after TURBT is recommended for NMIBC in the current European Association of Urology guidelines.9 In addition, Chang et al. reported that single‐dose instillation of chemotherapy can reduce bladder cancer recurrence in patients who have undergone nephroureterectomy.10,11 Urethral cutting is a mandatory operation during RC, and this procedure may lead to tumor cell extravasation. The purpose of instillation is to prevent plant metastasis by destroying free‐floating or superficial cells in the bladder. The implantation of monoclonal, proliferating tumor cells into the urothelium is considered to potentially be the primary cause of recurrence.11,12 The effectiveness of intraoperative intravesical chemotherapy is important, but understudied, for preventing TI - Singe intraoperative instillation of chemotherapy during radical cystectomy for bladder cancer: Oncological outcome and survival predictors JF - Cancer Medicine DO - 10.1002/cam4.5895 DA - 2023-06-01 UR - https://www.deepdyve.com/lp/wiley/singe-intraoperative-instillation-of-chemotherapy-during-radical-aLHg7zaTT8 SP - 12084 EP - 12094 VL - 12 IS - 11 DP - DeepDyve ER -